South Korea Antidiabetics Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (GLP-1 Receptor Agonists and Insulin), By Diabetes Type (Type 1 and Type 2), By Route of Administration (Oral and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and South Korea Antidiabetics Market Insights, Industry Trend, Forecasts to 2035

South Korea Antidiabetics Market Insights Forecasts to 2035

• The South Korea Antidiabetics Market Size Was Estimated at USD 1,452.6 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 11.88% from 2025 to 2035
• The South Korea Antidiabetics Market Size is Expected to Reach USD 4,996.1 Million by 2035

According to a research report published by Spherical Insights and Consulting, The South Korea Antidiabetics Market size is anticipated to reach USD 4,996.1 Million by 2035, growing at a CAGR of 11.88% from 2025 to 2035. Rising diabetes prevalence, improvements in SGLT2 inhibitors and GLP-1 receptor agonists, and growing use of combination therapy are the main drivers of the antidiabetics market. The proliferation of biosimilar insulin, regulatory approvals, and cardiovascular advantages all contribute to market growth.

Market Overview

The antidiabetics market refers to the industry focused on the development, production, and distribution of medications used to manage diabetes, particularly Type 1 and Type 2. This market plays a critical role in improving patient outcomes by helping regulate blood sugar levels and preventing complications. Enhanced quality of life, reduced healthcare costs, and lower risk of diabetes-related conditions. Growing awareness, rising diabetes prevalence, and advances in drug development present significant opportunities for market expansion. Governments are supporting the sector through initiatives like subsidies, public awareness campaigns, and funding for research and innovation. These efforts aim to reduce disease burden and promote early diagnosis and effective treatment, ultimately strengthening healthcare systems and boosting market growth.

Report Coverage

This research report categorizes the market for South Korea antidiabetics market based on various segments and regions forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea antidiabetics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea antidiabetics market.

Driving Factors        

The South Korea antidiabetics market is driven by the rising prevalence of diabetes, largely due to aging populations, sedentary lifestyles, and unhealthy diets. Increasing awareness about diabetes management, advancements in drug formulations, and the growing adoption of insulin and oral antidiabetic drugs drive market growth. Additionally, supportive government policies, expanding healthcare infrastructure, and rising investments in research and development contribute significantly. The demand for personalized medicine and innovative delivery systems further accelerates the market's expansion across both developed and emerging regions.

Restraining Factors         

The antidiabetics market faces several challenges that may impede its growth. High medication costs, particularly for newer formulations, can limit access for patients, especially in low-income regions, leading to disparities in diabetes care. Stringent regulatory requirements and lengthy approval processes for new drugs can delay market entry and increase costs for manufacturers. Safety concerns, such as the risk of adverse effects associated with certain antidiabetic drugs, may deter patient adherence and affect market acceptance. Furthermore, the prevalence of alternative treatment options, including lifestyle modifications and complementary therapies, may influence patient preferences and impact the demand for pharmaceutical interventions.

Market Segmentation

The South Korea Antidiabetics Market share is classified into drug class, diabetes type, route of administration, and distribution channel.

• The GLP-1 receptor agonists segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea antidiabetics market is segmented by drug class into GLP-1 receptor agonists and insulin. Among these, the GLP-1 receptor agonists segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The combined advantages in weight loss and glycemic control, both of which are essential for the management of type 2 diabetes. These medications, which include semaglutide and liraglutide, decrease stomach emptying, increase insulin secretion, and inhibit glucagon. Their popularity has been further reinforced by the cardiovascular benefits they have shown in significant clinical trials.

• The type 1 segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea antidiabetics market is segmented by diabetes type into type 1 and type 2. Among these, the type 1 segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. In continuous glucose monitoring devices, insulin delivery systems, and heightened knowledge of early illness detection and treatment. Patient outcomes and adherence are being improved by advancements in insulin analogs and better access to medication.

• The intravenous segment dominated share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea antidiabetics market is segmented by route of administration into oral and intravenous. Among these, the intravenous segment dominated share in 2024 and is expected to grow at a significant CAGR during the forecast period. Intravenous injection was commonly used in hospitals and emergency rooms for its quick therapeutic effects, particularly for patients who needed glycemic control right away. Improved access to healthcare facilities in emerging nations and rising hospitalization rates associated with complications from diabetes further bolstered the segment's growth.

• The hospital pharmacies segment held a majority share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea antidiabetics market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment held a majority share in 2024 and is expected to grow at a significant CAGR during the forecast period. A large number of prescriptions are written and given in hospital settings, particularly for patients in need of combination medications or specialized diabetes care. Additionally, hospitals serve as the main treatment facilities for patients with recent diagnoses and those who have serious problems, which results in a rise in the prescription of antidiabetic medications.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea antidiabetics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Helixmith Co., Ltd.
• Chong Kun Dang Pharmaceutical Corp.
• Daewoong Pharmaceutical Co., Ltd.
• GC Biopharma (Green Cross Corporation)
• Yuhan Corporation
• Samsung Biologics
• Hanmi Pharmaceutical
• Celltrion
• SK Biopharmaceuticals
• Hanall Biopharma
• Medytox
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea antidiabetics market based on the below-mentioned segments: 

South Korea Antidiabetics Market, By Drug Class

• GLP-1 Receptor Agonists
• Insulin

South Korea Antidiabetics Market, By Diabetes Type

• Type 1
• Type 2

South Korea Antidiabetics Market, By Route of Administration

• Oral
• Intravenous

South Korea Antidiabetics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies